Candel Therapeutics Expands Research Advisory Board with Dr. Jaffee
Candel Therapeutics Expands Research Advisory Board with Dr. Jaffee
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ: CADL), a biopharmaceutical company at the forefront of developing innovative immunotherapies to combat cancer, recently welcomed Elizabeth M. Jaffee, M.D., to its prestigious Research Advisory Board (RAB). This strategic move aims to bolster the Company’s focus on treating borderline resectable pancreatic cancer.
Dr. Elizabeth M. Jaffee: A Leader in Cancer Research
As an esteemed figure in the field of cancer immunology, Dr. Jaffee currently holds significant positions at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, where she directs the Gastrointestinal Cancers Program and serves as the Deputy Director. Her trailblazing work on immunotherapies specifically targeting pancreatic cancer has positioned her as a leading expert, with ongoing research dedicated to clinical trials that analyze how biomarkers can inform treatment strategies.
Contributions to Cancer Research Organizations
Dr. Jaffee's leadership extends beyond her clinical responsibilities. She previously presided over the American Association for Cancer Research and has actively participated in major initiatives like the Biden Moonshot Blue Ribbon Panel. Additionally, she plays a vital role as Chief Medical Advisor to the Lustgarten Foundation for Pancreatic Cancer Research, contributing her insights to ground-breaking advancements in the field.
Enhancing Candel’s Mission
Paul Peter Tak, M.D., Ph.D., FMedSci, the President and CEO of Candel, expressed enthusiasm about Dr. Jaffee's inclusion in the RAB, stating that her expertise aligns seamlessly with Candel’s mission. The Company recently reported promising survival data from its CAN-2409 clinical program, which targets borderline resectable pancreatic cancer. Dr. Jaffee's extensive knowledge is expected to substantially influence the design and implementation of late-stage clinical trials aimed at optimizing treatment outcomes.
Innovative Cancer Treatments at Candel
Candel Therapeutics is dedicated to developing off-the-shelf multimodal biological therapies designed to elicit a personalized immune response against tumors. With two clinical-stage immunotherapy platforms leveraging genetically modified adenovirus and Herpes simplex virus (HSV), Candel is paving the way for innovative treatments. The lead product candidate, CAN-2409, has shown statistically significant outcomes in recent trials. In a randomized phase 2a trial focusing on borderline resectable pancreatic cancer, patients receiving CAN-2409 combined with standard care exhibited significantly improved median overall survival rates compared to those receiving standard care alone.
Advancements in Cancer Immunotherapy
The Company is also developing CAN-3110, the lead candidate from its HSV platform, which is currently undergoing a phase 1b clinical trial for recurrent high-grade glioma. Candel’s enLIGHTEN™ Discovery Platform systematically explores new viral immunotherapies, employing cutting-edge human biological insights and analytics to create significant advances in treating solid tumors.
Looking Ahead
As Candel continues to forge its path in clinical development, the insights from Dr. Jaffee and the dedicated RAB promise to amplify the Company’s efforts to deliver breakthrough immunotherapy solutions to patients battling cancer.
Frequently Asked Questions
What is the role of Elizabeth Jaffee at Candel Therapeutics?
Dr. Elizabeth Jaffee has joined Candel's Research Advisory Board to provide expertise in cancer immunology and pancreatic cancer research.
What is CAN-2409?
CAN-2409 is Candel's lead product candidate designed to treat borderline resectable pancreatic cancer, showing promise in recent clinical trials.
What therapeutic approaches does Candel Therapeutics focus on?
Candel focuses on developing multimodal biological immunotherapies that elicit a systemic anti-tumor immune response to treat various cancers.
How has Dr. Jaffee contributed to cancer research?
Dr. Jaffee has made significant contributions through her roles in leading cancer organizations and her pioneering research on immunotherapy for pancreatic cancer.
Where can I learn more about Candel Therapeutics?
For more information about Candel Therapeutics, you can visit their official website at www.candeltx.com.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
